News · 26 weeks80+27%
2025-10-262026-04-19
Mix3290d
- Other12(38%)
- SEC Filings8(25%)
- Insider7(22%)
- Earnings3(9%)
- Leadership2(6%)
Latest news
25 items- PRZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expressionConfirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum resistant ovarian cancerMedian duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.6 months in ovarian and endometrial cancer cohortsFavorable tolerability profile and broad therapeutic window support continued clinical development VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a div
- PRZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformSix poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple solid tumor models New programs include Ly6E, CLDN18.2, and PTK7-targeting ADCs, as well as novel payload and platform innovations New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherape
- PRZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr
- SECSEC Form SCHEDULE 13G filed by Zymeworks Inc.SCHEDULE 13G - Zymeworks Inc. (0001937653) (Subject)
- INSIDERSEC Form 4 filed by Schayowitz Adam4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 4 filed by Platshon Scott4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 3 filed by new insider Platshon Scott3 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schayowitz Adam3 - Zymeworks Inc. (0001937653) (Issuer)
- PRZymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e
- INSIDERSEC Form 4 filed by Stafford Kristin4 - Zymeworks Inc. (0001937653) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stafford Kristin3 - Zymeworks Inc. (0001937653) (Issuer)
- SECSEC Form 8-K filed by Zymeworks Inc.8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks Appoints Kristin Stafford as Chief Financial OfficerVANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a
- PRZymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug ConjugateU.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC) Ongoing Phase 1 clinical trial of ZW191 enrolling patients with advanced solid tumors to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA
- PRZymeworks Announces Participation in Upcoming Investor ConferencesVANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Needham 25th Annual Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 15 at 10:15 am Eastern Time (ET).2026 Bloom Burton & Co. Healthcare Investor Conference: Zymework's management will participate in one-on-one meetings and present on April 21 in Toronto, ON. About Zymeworks I
- PRZymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual MeetingVANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the company's partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera® (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA. "We are pleased to see the continued clinical progress of zanidatamab reflected in multiple presentations at AACR," said Ken Galbraith, Chair, Chief Executive Off
- PRZymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual MeetingNew clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting antibody-drug conjugate (ADC)New ADC candidates, including ZW437 and ZW418, demonstrate strong activity across RAS-mutated cancers based on a novel pan-RAS inhibitor ADC platform VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts
- SECSEC Form 144 filed by Zymeworks Inc.144 - Zymeworks Inc. (0001937653) (Subject)
- SECSEC Form S-8 filed by Zymeworks Inc.S-8 - Zymeworks Inc. (0001937653) (Filer)
- SECZymeworks Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure8-K - Zymeworks Inc. (0001937653) (Filer)
- SECSEC Form 10-K filed by Zymeworks Inc.10-K - Zymeworks Inc. (0001937653) (Filer)
- PRRoyalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note FinancingZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zymeworks Inc. (NASDAQ:ZYME) today announced an agre
- SECZymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zymeworks Inc. (0001937653) (Filer)
- PRZymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note FinancingZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agre
- PRZymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsSupplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed